Gerresheimer's €1.5bn Divestment: A Balance-Sheet Rescue Priced at a Fraction of the Proceeds
Published on 08/08/2026 at 16:34 | Redaktion boerse-global.de
The arithmetic is striking. Gerresheimer has agreed to sell two business divisions for roughly €1.5 billion — yet the entire company trades on the Frankfurt exchange at a market capitalization of just €916.69 million. That gap, between what a consortium advised by Apax Partners is willing to pay for a quarter of the group's revenue and what investors currently assign to everything else, frames the central tension in the Düsseldorf-based packaging group's turnaround story.
The deal, signed on July 29, covers the Centor business and the global Primary Packaging Plastics operations. Together, those units generated around €570 million in sales in 2025 — more than a quarter of group revenue — and employ roughly 2,400 people across 16 plants in nine countries. The transaction is structured in two stages: Centor is expected to close by the end of the current fiscal year, while the plastics disposal follows in the first half of 2027. Management has signaled that the proceeds will go primarily toward paying down debt.
A sale born of necessity, not strength
This is not a divestment executed from a position of confidence. Gerresheimer has spent much of the year grappling with an accounting scandal that has eroded investor trust and forced a strategic retreat. In February, the company flagged impairment charges of €220 million to €240 million after discovering that accounting irregularities were more extensive than initially thought. The BaFin, Germany's financial regulator, subsequently widened its probe to examine both the 2024 consolidated financial statements and the 2025 half-year report, with particular attention to lease liabilities carrying a book value of €65.5 million, potentially misstated useful lives of capitalized development costs worth €29.4 million, and €196.5 million in impaired assets in the Advanced Technologies segment that had not been written down.
The fallout was swift. In April, Gerresheimer was forced to exit the SDax after failing to deliver its 2024/25 annual report on time — a visible blow to its standing. When the audited accounts finally landed at the end of June, they came with a lowered outlook for 2026: revenue in the lower half of the €2.3 billion to €2.4 billion range, an adjusted EBITDA margin of 17 to 18 percent, and a free cash flow that is expected to be negative, between minus €50 million and minus €100 million, partly due to reduced factoring volumes.
The market's verdict
Investors have not been forgiving. The shares closed Friday at €26.34, down 0.83 percent on the day and roughly 9.92 percent lower over the past month. On a twelve-month basis, the stock has lost 41.75 percent of its value. The recent slide has been relentless enough that the equity now sits just 7.33 percent above its 200-day moving average — a thin cushion that chart watchers note could signal either a forming base or a prelude to further weakness.
Analyst sentiment reflects the uncertainty. In late May, Jefferies downgraded the stock from Buy to Hold, cutting its price target from €34.10 to €26.80, citing delays in integrating the Bormioli acquisition and risks around capacity expansion. By contrast, LBBW raised its price target from €23 to €28 in early July while keeping a Hold rating — a modest vote of confidence following the first signs of a deleveraging path, but hardly an endorsement of a swift recovery.
When a company's financial controls come under scrutiny, the same principle applies to workplace safety: documentation is everything. A free Health & Safety Toolkit provides ready-to-use risk assessments and checklists aligned with UK regulations like the Health & Safety at Work Act 1974, helping you protect your team and avoid costly enforcement action. Download the free Health & Safety Toolkit
What the deal does — and doesn't — solve
For shareholders, the critical question is whether the Apax proceeds can arrive quickly enough to offset the cash drain elsewhere. The staggered transaction structure means debt reduction will come in installments, not as a single event. In the meantime, the company's own guidance points to negative free cash flow in 2026, and the reduced factoring volume will remove a previously available source of liquidity. If the Centor closing slips beyond year-end, or if the BaFin probe surfaces fresh problems, the balance-sheet relief could be partially eroded before it becomes visible.
There are, however, reasons for cautious optimism. The fact that Silgan Holdings, a US packaging group, made a takeover approach in March — one that Gerresheimer rejected in favor of pursuing the Centor sale and debt reduction — suggests strategic buyers see value in the underlying assets. And should the BaFin investigation conclude without further material findings, a significant overhang on the stock would be removed.
The next checkpoint
The virtual annual general meeting on September 1 offers the first formal opportunity for management to defend its strategy and address the deleveraging timeline directly. Between now and then, the share price is likely to remain hostage to two variables: the pace of the Centor transaction and the flow of regulatory disclosures. If both move in the company's favor, the stock could stabilize near its long-term average. If either falters, the February lows may once again come into view. The €1.5 billion sale is a substantial step — but it is the execution, not the announcement, that will determine whether this marks the beginning of a genuine reset or merely another chapter in a story dominated by broken trust.
